Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
8 NC counties are under alert, including Johnston County.
Breaking News
RFK Jr. plans to drop out of 2024 presidential race and endorse Trump, NBC News reports
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lantern Pharma
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
August 07, 2024
From
Lantern Pharma
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
August 05, 2024
From
Lantern Pharma
Via
Business Wire
Tickers
LTRN
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
July 10, 2024
From
Lantern Pharma
Via
Business Wire
Tickers
LTRN
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
January 17, 2024
From
Lantern Pharma
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
October 03, 2023
From
Lantern Pharma
Via
Business Wire
Tickers
LTRN
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
June 08, 2023
From
Lantern Pharma
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
March 08, 2023
From
Lantern Pharma
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
September 30, 2021
From
Lantern Pharma
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tickers
LTRN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.